ABIVAX_Logo-RGB.png
Abivax announces the resumption of its liquidity contract
November 21, 2023 02:30 ET | Abivax
Abivax announces the resumption of its liquidity contract Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage...
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023 08:00 ET | Abivax
PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics...
ABIVAX to Host Key O
ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy
November 22, 2016 15:30 ET | ABIVAX
PARIS, Nov. 22, 2016 (GLOBE NEWSWIRE) -- ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announced...